Patient-Centered Approach to Benefit–Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non–Small-Cell Lung Cancer

This work summarizes the benefit and risk of the results of clinical trials submitted to the US Food and Drug Administration of therapies for the treatment of non–small cell lung cancer (NSCLC) using number needed to benefit (NNB) and number needed to harm (NNH) metrics. NNB and NNH metrics have bee...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JCO Clin Cancer Inform
Main Authors: Raju, Gokaraju K., Khozin, Sean, Gurumurthi, Karthik, Domike, Reuben, Woodcock, Janet
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2020
Assuntos:
Review Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7469613/
https://ncbi.nlm.nih.gov/pubmed/32853030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/CCI.19.00103
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares